EQS Group-Ad-hoc: Medacta Group SA / Key word(s): Product Launch
Medacta Enters U.S. and Australian Sports Medicine Market with Dynamic
Lineup of Surgical Solutions
30-Jul-2019 / 19:00 CET/CEST
Release of an ad hoc announcement pursuant to Art. 53 KR
The issuer is solely responsible for the content of this announcement.
*Press Release*
*Medacta Enters U.S. and Australian Sports Medicine Market with Dynamic
Lineup of Surgical Solutions*
_CASTEL SAN PIETRO, 30 July 2019_- Building on 20 years of innovation in
joint replacement and spinal surgery, Medacta International will enter the
United States and Australian sports medicine markets. Medacta is actively
expanding upon its products and building out what will become a robust
portfolio. Its most recent sports medicine offerings, the MectaLock PEEK
Suture Anchor and the MectaScrew PEEK Interference Screw, have received
clearance from the U.S. Food and Drug Administration (FDA) and obtained the
Australian Therapeutic Goods Administration (TGA) registration. They are now
being introduced in the U.S. and Australian markets.
"Medacta is known for developing personalized orthopedic surgery solutions
and providing a high level of support to the surgeons who adopt them," said
Francesco Siccardi, Chief Executive Officer of Medacta International. "We
look forward to applying our expertise to this new area, the next natural
market for Medacta to enter following the success of our surgeon- and
patient-friendly solutions across hip, knee, shoulder and spine."
The MectaLock PEEK Suture Anchor is an implantable device used for soft
tissue re-fixation in acetabular labral repairs in the hip and glenoid
labrum repairs in the shoulder. The portfolio is complete and comprehensive,
to accommodate different patient anatomies and surgeon preferences.
The MectaScrew PEEK Interference Screw is indicated for reconstructive
treatment of ruptured anterior and posterior cruciate ligaments by means of
auto- and allografts. The MectaScrew, together with the M-ARS ACL (Medacta
Anatomic Ribbon Surgery) which received FDA clearance in 2018, is intended
to be used for knee arthroscopy.
Medacta intends to continue growing its portfolio in sports medicine,
utilizing its expertise in orthopaedics to develop personalized,
minimally-invasive solutions.
*For inquiries*
Medacta Group SA
Corrado Farsetta, CFO
Phone: +41 91 696 60 60
investor.relations@medacta.ch
*About Medacta *
Medacta is an international orthopaedics company specializing in the design
and production of innovative orthopaedic products and the development of
accompanying surgical techniques. Established in 1999 in Switzerland,
Medacta's products and surgical techniques are characterized by innovation.
Medacta is a pioneer in developing new offerings on the basis of minimally
invasive surgical techniques, in particular its Anterior Minimally Invasive
Surgery ("AMIS") technique for hip replacements. Medacta has leveraged its
orthopedic expertise and comprehensive understanding of the human body to
develop the sophisticated "MySolutions" technology, which offers surgeons
highly personalized pre-operative planning and implant placement
methodologies by creating advanced personalized kinematic models and 3D
planning tools for use in hip, knee, shoulder and spine procedures. Medacta
is headquartered in Castel San Pietro, Switzerland, and employs
approximately 970 people. To learn more about Medacta, please visit
www.medacta.com
End of ad hoc announcement
Language: English
Company: Medacta Group SA
Strada Regina
6874 Castel San Pietro
Switzerland
Phone: +41 696 6060
E-mail: info@medacta.ch, investor.relations@medacta.ch
Internet: www.medacta.com
ISIN: CH0468525222
Listed: SIX Swiss Exchange
EQS News ID: 848827
End of Announcement EQS Group News Service
848827 30-Jul-2019 CET/CEST
(END) Dow Jones Newswires
July 30, 2019 13:00 ET (17:00 GMT)
